Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CI4E
|
|||
| Former ID |
DCL000592
|
|||
| Drug Name |
Pertuzumab
|
|||
| Synonyms |
Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Approved | [1], [2] | |
| Company |
Roche; Genentech
|
|||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01744 | |||
| SuperDrug ATC ID |
L01XC13
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046). | |||
| REF 2 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. | |||
| REF 3 | Clinical pipeline report, company report or official report of Roche (2009). | |||
| REF 4 | Pertuzumab. Drugs Fut 2008, 33(2): 123 ISSN 0377-8282. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.